氟茚二酮(Fluindione) - 药物靶点：VKOR_在研适应症：凝血障碍_专利_临床

概要

基本信息

药物类型

小分子化药

别名

2-(4-fluorophenyl)indene-1,3-dione、Previscan

靶点

VKOR

作用方式

抑制剂

作用机制

VKOR抑制剂(维生素K环氧化物还原酶复合体1抑制剂)

治疗领域

血液及淋巴系统疾病

在研适应症

凝血障碍

非在研适应症-

原研机构-

在研机构-

非在研机构-

权益机构-

最高研发阶段批准上市

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C15H9FO2

InChIKeyNASXCEITKQITLD-UHFFFAOYSA-N

CAS号957-56-2

关联

2

项与氟茚二酮相关的临床试验

NCT02286414

/ CompletedN/AIIT

Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in the Treatment of Non Valvular Atrial Fibrillation in Patients Aged 80 Years and Over, Living at Home or in Nursing Home. A Prospective Cohort Study

The aim of the study is to compare, in real life, the risk benefit (including both major bleeding and thrombotic events (TE) and death from any cause) associated with direct oral anticoagulants (DOA) and with anti vitamin K (VKA) in older adults (≥ 80 years) suffering from non valvular atrial fibrillation and living in community or nursing home settings.
An observational multicenter prospective inception cohort will be conducted within the PRESAGE-Network, an ongoing active network on drug safety in older adults in France involving a sample of general practitioners (GPs) and pharmacists, for an active surveillance of drug safety in older adults. GPs and pharmacists will prospectively include all octo+ patients they care for, newly treated with an oral anticoagulant (VKA or DOA) for nv AF and will follow them during 2 years at least.

开始日期2015-02-01

申办/合作机构

Assistance Publique des Hôpitaux de Paris SA

NCT00966290

/ Completed临床4期IIT

Anticoagulant Clinic-based Shared-care Versus Usual Cate Management of Vitamin K Antagonist Therapy : the Open, Randomized Multicenter Study

Background: Whether the management of vitamin K antagonists (VKA) therapy by general practitioners with the collaboration of anticoagulation clinics (ACC) provides better clinical outcomes than that accomplished by general practitioners alone (usual care [UC] management) is not clear.
Objectives: To compare ACC-based shared-care management with UC management of VKA therapy with respect to clinical events.
Patients/Methods: Open, randomized, multicenter study in patients starting VKA therapy for at least three months. The primary study outcome is a composite of confirmed symptomatic thromboembolic or major bleeding events. All-cause mortality is a secondary outcome. All outcomes are reviewed by a central, independent adjudication committee.

开始日期2003-02-01

申办/合作机构

Toulouse University Hospital

100 项与氟茚二酮相关的临床结果

登录后查看更多信息

100 项与氟茚二酮相关的转化医学

登录后查看更多信息

100 项与氟茚二酮相关的专利（医药）

登录后查看更多信息

276

项与氟茚二酮相关的文献（医药）

2025-05-01·Journal of Pharmaceutical and Biomedical Analysis

Simultaneous quantification of eighteen therapeutic oral anticoagulants, rodenticides, and antiplatelet agents by LC-MS/MS and its application in post-mortem forensic cases

Article

作者: Delavenne, Xavier ; Bidat, Carolyne ; Escal, Jean ; Hodin, Sophie ; Duband, Sébastien ; Drague, Angélique ; Dellinger, Sandrine ; Feliu, Catherine

Anticoagulants and antiplatelet agents, which interfere with blood coagulation, can lead to fatal bleeding. Moreover, their widespread use as drugs or rodenticides poses a high risk of accidental or intentional poisoning. Therefore, quantifying these substances is essential in forensic investigations. This research aimed to develop and validate a liquid chromatography-tandem mass spectrometry method capable of quantifying eighteen anticoagulant or antiplatelet compounds (apixaban, rivaroxaban, dabigatran, warfarin, acenocoumarol, fluindione, brodifacoum, bromadiolone, difenacoum, difethialone, chlorophacinone, coumatetralyl, flocoumafen, acetylsalicylic acid, clopidogrel, dipyridamole, ticagrelor, and ticlopidine) in a single run with simple sample preparation. The method was validated according to the FDA recommendations for all compounds, with an eight-min run time in human whole blood, the gold standard in toxicological forensic investigation. The method was also validated for therapeutic compounds and most rodenticides in bile and vitreous humor. Following validation, the method was applied to seven forensic cases with a known history of anticoagulant or antiplatelet agent use to prove the validity of the method. This method provides a valuable tool for legal contexts where precise determination of anticoagulant compound presence and concentration is required.

2025-01-24·European Journal of Organic Chemistry

Synthesis of 1,4‐Naphthoquinones via Palladium(II)‐Catalyzed Tertiary C−H Alkylation of Olefins Followed by C−C Bond Cleavage

作者: Li, Wenguang ; Chang, Mengfan ; Zhang, Xu ; Xu, Xuefeng ; Li, Ting ; Ni, Tongtong

AbstractAn efficient method has been developed for the preparation of 1,4‐naphthoquinones via a palladium‐catalyzed reaction of 2‐aryl‐1,3‐indandiones with olefins. This reaction involves the tertiary C−H alkylation of 2‐aryl‐1,3‐indandiones with olefins to produce a tertiary alcohol, followed by C−C bond cleavage.

2024-12-01·Biomedicine & Pharmacotherapy

Population pharmacokinetics of unfractionated heparin and multivariable analysis of activated clotting time in patients undergoing radiofrequency ablation of atrial fibrillation

Article

作者: Lesaffre, François ; Feliu, Catherine ; Dubuisson, Florine ; Djerada, Zoubir ; Konecki, Celine ; Guillou, Sophie ; Faroux, Laurent ; Labdaoui, Moad

INTRODUCTIONAtrial fibrillation (AF) increases cardiovascular morbidity and mortality. To reduce thrombosis and bleeding risks, and due to high variability of unfractionated heparin (UFH) effect, activated clotting time (ACT) is used during radiofrequency catheter ablation (RFCA) of AF to guide UFH dose. This study aimed to develop a population PK-PD model and perform multivariable analysis in order to identify the most significant covariates associated with interindividual variability of UFH.METHODSElectronic medical records from 668 patients undergoing RFCA were analyzed, including relevant covariates. The relationship between UFH dose and ACT and the impact of the main covariates were characterized using a mixed-effect PK-PD model. Multivariable analysis was then used to identify predictors of ACT 15 minutes after UFH administration (ACT15).RESULTSA two-compartment PK model with linear elimination and a direct Emax PD model with a baseline and sigmoidicity best described the observed ACT values. Pretreatment with dabigatran, warfarin, or fluindione significantly influenced baseline ACT. Pretreatment with vitamin K antagonists or low molecular weight heparin explained Emax variability. The multivariable model identified baseline ACT, initial UFH dose, and previous anticoagulant as the main predictors of ACT15. Model evaluation through resampling and external validation showed accurate ACT15 predictions.CONCLUSIONThis study presents the first population PK-PD model characterizing the relationship between UFH doses and ACT during RFCA, along with multivariable analysis. Additionally, predictive calculators for ACT15 and UFH dose based on patient and procedural characteristics were developed, enhancing personalized anticoagulation management during RFCA.

100 项与氟茚二酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	氟茚二酮	B01AA12	DB13136

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
凝血障碍	法国	-	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASN2014	N/A	肾病	7	Fluindione	醖糧製艱選壓選築網餘(餘築餘淵淵鬱餘壓構鑰) = WRN was initially suspected in patients treated with warfarin while initial diagnosis was incorrect in 4 of 5 patients treated with fluindione (acute interstitial nephritis for 3 patients and acute tubular necrosis for the last patient) 膚廠觸鹹淵鬱繭願鹽鹽 (範窪蓋醖齋夢憲積願繭 ) 更多	不佳	2014-11-11